CVS Health Corp


Want a discount? Become a member by purchasing Annual Subscription!
SKU: CVS Category:


CVS had another strong quarter surpassing Wall Street expectations as it continued to witness a robust demand for COVID-19 tests and vaccines, administered at its pharmacies and clinics. This demand might be slower in the latter half of 2021 but the Delta variant could be an important factor that could benefit the company. The company witnessed a double-digit growth in almost all its segments but Covid-related costs did weigh upon its Aetna health insurance unit. It is worth mentioning that CVS has moved far beyond the traditional drugstore model in order to stay competitive with the likes of Amazon and other online drug retailers. It has evolved into a full-fledged healthcare conglomerate and new CEO Karen Lynch has been explicit in passing on this message to the markets. The company’s recent nationwide launch of the Aetna Virtual Primary Care is a major stride within the telehealth space. We continue to be bullish on CVS and maintain our ‘Buy’ rating with a revised target price.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $496 annual subscription!